PubMed Health⌕ Search

PubMed · 10894025

[Hypercalcemia].

Abstract

Hypercalcemia may develop as a consequence of a disturbance of one or more links within the feedback system of calcium homeostasis. Hypercalcemic diseases may be caused by the parathyroid glands as well as by their dependent end organs, the kidneys, the intestine, the skeleton. Partial parathyroid hormone activity can be produced by many tumour factors in a paraneoplastic way. Hypercalcemia induces the symptoms of the so-called hypercalcemic syndrome which should be familiar to the physician. Hints towards the cause may be the organ manifestation in case of primary hyperparathyroidism, in case of the other causal diseases they may present with typical components of their clinical picture. Diagnostics should start with the differentiation between parathyroid-related hypercalcemia (autonomous, primary hyperparathyroidism and variants) and the broad spectrum of non-parathyroid hypercalcemia, mainly accompanying malignancies. Symptomatic treatment of hypercalcemia often has to start before the definite diagnosis is confirmed. Later on, this merely symptomatic treatment may be replaced by causal treatment, as far as possible. Symptomatic treatment of hypercalcemia may follow the 'diuretic', the 'antiresorptive', or the 'antiabsorptive' way--the 'extractive' way by hemodialysis is the treatment of choice in case of hypercalcemic crisis accompanied by renal insufficiency.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Ziegler. 2000. [Hypercalcemia].. https://doi.org/10.1024/0040-5930.57.6.391

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer.

OBJECTIVE: To review the evidence for the use of bisphosphonates to reduce skeletal morbidity in cancer patients with bone metastases. DATA SOURCES: Electronic databases, scanning reference lists, and consultation with experts and pharmaceutical companies. Foreign language papers were included. STUDY SELECTION: Included trials were randomised controlled trials of patients with malignant disease and bone metastases who were treated with oral or intravenous bisphosphonate compared with another bisphosphonate, placebo, or standard care. All trials measured at least one outcome of skeletal morbidity. RESULTS: 95 articles were identified; 30 studies fulfilled inclusion criteria. In studies that lasted > or = 6 months, compared with placebo bisphosphonates significantly reduced the odds ratio for fractures (vertebral 0.69, 95% confidence interval 0.57 to 0.84, P < 0.0001; non-vertebral 0.65, 0.54 to 0.79, P < 0.0001; combined 0.65, 0.55 to 0.78, P < 0.0001), radiotherapy (0.67, 0.57 to 0.79, P < 0.0001), and hypercalcaemia (0.54, 0.36 to 0.81, P = 0.003) but not for orthopaedic surgery (0.70, 0.46 to 1.05, P = 0.086) or spinal cord compression (0.71, 0.47 to 1.08, P = 0.113). The reduction in orthopaedic surgery was significant in studies that lasted over a year (0.59, 0.39 to 0.88, P = 0.009). Use of bisphosphonates significantly increased time to first skeletal related event but did not increase survival. Subanalyses showed that most evidence supports use of intravenous aminobisphosphonates. CONCLUSIONS: In people with metastatic bone disease bisphosphonates significantly decrease skeletal morbidity, except for spinal cord compression and increased time to first skeletal related event. Treatment should start when bone metastases are diagnosed and continue until it is no longer clinically relevant.

Bone Neoplasms↗

Myeloid sarcoma of both kidneys, the brain, and multiple bones in a nonleukemic child.

A myeloid sarcoma (MS) is an extramedullary tumor consisting of primitive granulocytic precursor cells. Although most such tumors have been reported in patients with acute myelogenous leukemia, MS is rarely recognized as an isolated tumor without any evidence of leukemia. However, in such cases, the initial diagnosis of MS can be difficult, so initial misdiagnosis rates of up to 75% have been reported. This report describes an unusual case of MS in a 3-year 5-month-old girl presenting as bilateral renal enlargements, and brain masses, with multiple bone involvements, but no hematological abnormalities.

Bone Neoplasms↗

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases.

Osteoblastic bone metastases are common in prostate and breast cancer patients, but mechanisms by which tumor cells stimulate new bone formation are unclear. We identified three breast cancer cell lines that cause osteoblastic metastases in a mouse model and secrete endothelin-1. Tumor-produced endothelin-1 stimulates new bone formation in vitro and osteoblastic metastases in vivo via the endothelin A receptor. Treatment with an orally active endothelin A receptor antagonist dramatically decreased bone metastases and tumor burden in mice inoculated with ZR-75-1 cells. Tumor-produced endothelin-1 may have a major role in the establishment of osteoblastic bone metastases, and endothelin A receptor blockade represents effective treatment.

Bone Neoplasms↗